Postdoctoral Research Fellow, Medical Biochemistry | uon/hmri | DIPG/DMG | #DunLab | rundipg.org
Joined May 2020
- Tweets 61
- Following 69
- Followers 105
- Likes 65
16 Photos and videos
Evie Jackson retweeted
29 Aug 2024
Congratulations to #DunLab's newest PhD student Yuanhao for receiving his first research award. I'm sure this is the first of many.
Thanks to #WarriorJack and @RUNDIPG for supporting Yuanhao's scholarship. @PrecisionMedUON @HMRIAustralia @UON_research
1
5
17
820
23 Aug 2024
I'm so honoured to be named a Col Reynolds ECR Fellow for 2024. Congrats to fellow recipients and huge thank you to @KidsCancerProj for their support. Also thank you to the support from the #DunLab as well as @MattDun17 and @duchatel_ryan. @PrecisionMedUON
@UON_research
21 Aug 2024
The Kids’ Cancer Project has committed over $7.6 million to support 24 of Australia’s top young scientists.
Watch the full video and learn more about the 2023 and 2024 cohort of Col Reynolds Fellows.
brnw.ch/21wLZbY
2
1
12
1,356
19 Jul 2024
So lucky to be a part of this amazing team!! I can't thank @MattDun17 or @duchatel_ryan more for how they've mentored me throughout my career.
19 Jul 2024
Ph #DunLab! So proud of @evierjackson graduating today! Our 1st incredible #DIPG #DMG student but nowhere near our last.
Enjoy EJ and thanks for your dedication, leadership and excellence.
Thanks @_IsabellaMarcus for EJ scholarship and to all our supporters and parents @RUNDIPG
2
3
23
970
Evie Jackson retweeted
19 Jul 2024
Ph #DunLab! So proud of @evierjackson graduating today! Our 1st incredible #DIPG #DMG student but nowhere near our last.
Enjoy EJ and thanks for your dedication, leadership and excellence.
Thanks @_IsabellaMarcus for EJ scholarship and to all our supporters and parents @RUNDIPG
5
44
2,693
8 Feb 2024
This work would not be at this calibre if not for our incredible collaborators, including @NazarianLabs and @JaseCain and all who funded and supported our research: @chadtough, @RUNDIPG, @Uni_Newcastle, @HMRIAustralia, @PrecisionMedUON, @DIPGCollab, @CureStartsNow... (12/13)
1
5
217
8 Feb 2024
5
203
8 Feb 2024
Here, we describe a clinically relevant combination therapy and highlight the inclusion of RT. Our results also provide the impetus for future studies targeting alterations to myelination and the immune environment due to combined paxalisib and enzastaurin. (11/13)
1
5
220
8 Feb 2024
Through investigating the chromatin architecture (ATAC-seq), we further validated these findings, showing that the treatment driving this proinflammatory landscape, much like patients diagnosed with multiple sclerosis, which is unsurprising given the OPC cell of origin. (9/13)
1
5
193
8 Feb 2024
Therefore, it is imperative to promote the benefit of radiation, our only current weapon against DIPG. Here, we treble the survival benefit of the combination by include RT, showing impressive tumor regression. (10/13)
1
6
184
8 Feb 2024
So excited to share our latest findings, just published in @jclinicalinvest! So proud of this work detailing the targeting of PI3K/mTOR with paxalisib, led by @duchatel_ryan, @evierjackson and @MattDun17. Follow this tweetorial for a summary: (1/13)
doi.org/10.1172/JCI170329.
2
5
17
11,364
8 Feb 2024
Additionally, we show genes critical to oligodendroglial myelination show significantly decreased expression in tumor tissue treatment with the combination, driving this proinflammatory landscape. (8/13)
1
4
158
8 Feb 2024
Here, we show increased TGFB1 and MHC II gene expression profiles, alongside increased STAT1 signaling, suggesting DIPG’s genetic dependence of PI3K signaling may promote immune escape through impacting antigen presentation. (7/13)
1
6
170
8 Feb 2024
Yet, although we show a synergistic survival benefit, mice still succumb of DIPG. Therefore, we assess therapeutic escape/plasticity via single cell spatial transcriptomics analysis using the @10xGenomics Xenium platform, showing high PDGFRA expression in tumor regions. (6/13)
1
2
11
1,399
8 Feb 2024
We performed global unbiased quantitative phosphoproteomic profiling of DIPG cells treated with paxalisib, confirming potent PI3K/Akt/mTOR pathway inhibition, whilst simultaneously activating PKC signaling, ameliorated using the PKC inhibitor, enzastaurin. (5/13)
1
5
213
8 Feb 2024
In line with in vitro analysis, the phosphorylation of pAKT (Thr308/Ser473) decreased in a dose-dependent manner. Treatment with optimized dosing of 5 mg/kg/b.i.d. maintained suppression of PI3K signaling to a similar level to that of 10 mg/kg/day. (4/13)
1
4
160
8 Feb 2024
Treatment of DIPG cell line models with paxalisib potently inhibited PI3K/Akt/mTOR phosphorylation, sustained for up to 24h post-treatment in vitro. (3/13)
1
5
238
8 Feb 2024
DIPG cells lines were significantly more sensitive to paxalisib than non-midline high grade gliomas, with normal controls [HCMEC/D3 BBB endothelial cells, HMC3 microglial cells and ReN neural progenitor cells] resistant to treatment at high dose. (2/13)
1
5
331
Evie Jackson retweeted
28 Nov 2023
We are extremely grateful to have received @MarkHughesFdn Brain Cancer Innovation Grant for our project "Utilising a translational nanopharmaceutics approach to improving drug delivery in DIPG" @MattDun17 @duchatel_ryan @evierjackson #LaurenArms markhughesfoundation.com.au/…
2
3
29
1,690
Evie Jackson retweeted
20 Nov 2023
The PNOC001 trial results on everolimus for children with progressive/recurrent pLGG and genomic biomarkers for progressive disease are now published in @JCO_ASCO ascopubs.org/doi/abs/10.1200…. Congratulations to the @PNOC_kids team! @UCSF_PBC @NeurosurgUCSF @epflSV @NCMMnews @NeuroOnc
18 Nov 2023
‼️ #SNO2023 simultaneous publication in #JCO by Mueller, et al:
Everolimus for Children with Recurrent or Progressive Low-Grade Glioma: Results from the Phase 2 PNOC001 Trial. brnw.ch/21wEyjN
4
21
4,966
21 Nov 2023
What an incredible opportunity to present our work at #SNO23, and and to receive an abstract award!
Thanks to all who have supported me and this work, especially @_RCDFoundation for the travel grant to attend. @MattDun17 @duchatel_ryan @_IsabellaMarcus @RUNDIPG
2
2
21
2,221